Conventional myelosuppressive chemotherapy for non-haematological malignancy disrupts the intestinal microbiome
Abstract Background The gut microbiota influences many aspects of host physiology, including immune regulation, and is predictive of outcomes in cancer patients. However, whether conventional myelosuppressive chemotherapy affects the gut microbiota in humans with non-haematological malignancy, indep...
Main Authors: | Lito E. Papanicolas, Sarah K. Sims, Steven L. Taylor, Sophie J. Miller, Christos S. Karapetis, Steve L. Wesselingh, David L. Gordon, Geraint B. Rogers |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-021-08296-4 |
Similar Items
-
Preventing empirical antibiotic treatment failure in migrant populations: screening by infection risk, not ethnic background
by: Steven L. Taylor, et al.
Published: (2023-09-01) -
Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
by: Estcourt, L, et al.
Published: (2015) -
Bacterial viability in faecal transplants: Which bacteria survive?Research in context
by: Lito E. Papanicolas, et al.
Published: (2019-03-01) -
A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
by: Crighton, GL, et al.
Published: (2015) -
Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation (Review)
by: Estcourt, L, et al.
Published: (2015)